Under the new plans, the company will expand its existing capabilities to include formulation development and Good Manufacturing Processes (GMP) contract manufacturing services for solid dispersions and oral solid dosages.
The expansion will include spray drying and extrusion processes, which were previously located at its Columbia facility.
The new facility expansions are expected to be completed by 2014 summer.
Ashland Specialty Ingredients president John Panichella said the expansion supports company’s commitment to ongoing investment in drug solubilization, which helps its customers to capitalize on future growth opportunities.
"Delaware’s recent decision to provide incentives to encourage Ashland’s growth demonstrates the state’s positive outlook and its commitment to business expansion in Delaware," Panichella added.
"I am extremely excited about the growth opportunities for our pharmaceutical product line and recognize that the state’s actions were integral to our decision."